
Anne Cathrine Bakken
- Research associate; MSc
- +47 2278 1711
I am involved in several projects in the genome biology group (planning of experiments and carrying these out in the laboratory). Additionally I have some routine work at the department. I perform several methods, including RNA and DNA isolation, cDNA synthesis, PCR (both standard and quantitative), Sanger sequencing, fragment analysis/capillary electrophoresis, and cell line authentication.
Academic degree:
2010: Msc in Molecular Biology, University of Oslo. "Exon-specific biomarkers in cancer: Experimental validation of exon microarray data from colorectal and testicular cancers"
Publications 2022
In situ expression of ERG protein in the context of tumor heterogeneity identifies prostate cancer patients with inferior prognosis
Mol Oncol (in press)
DOI 10.1002/1878-0261.13225, PubMed 35574900
Publications 2021
High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity
Neoplasia, 23 (6), 634-641
DOI 10.1016/j.neo.2021.05.012, PubMed 34107378
Publications 2019
Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer
Sci Rep, 9 (1), 13579
DOI 10.1038/s41598-019-49964-7, PubMed 31537872
Publications 2018
Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity
Eur Urol, 75 (3), 498-505
DOI 10.1016/j.eururo.2018.08.009, PubMed 30181068
Publications 2017
Novel transcription-induced fusion RNAs in prostate cancer
Oncotarget, 8 (30), 49133-49143
DOI 10.18632/oncotarget.17099, PubMed 28467780
Publications 2014
High frequency of fusion transcripts involving TCF7L2 in colorectal cancer: novel fusion partner and splice variants
PLoS One, 9 (3), e91264
DOI 10.1371/journal.pone.0091264, PubMed 24608966
Publications 2013
Transforming pluripotency: an exon-level study of malignancy-specific transcripts in human embryonal carcinoma and embryonic stem cells
Stem Cells Dev, 22 (7), 1136-46
DOI 10.1089/scd.2012.0369, PubMed 23137282
Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer
Neoplasia, 15 (7), 720-6
DOI 10.1593/neo.13232, PubMed 23814484
Publications 2012
The exon-level biomarker SLC39A14 has organ-confined cancer-specificity in colorectal cancer
Int J Cancer, 131 (6), 1479-85
DOI 10.1002/ijc.27399, PubMed 22173985
Publications 2011
Fusion gene microarray reveals cancer type-specificity among fusion genes
Genes Chromosomes Cancer, 50 (5), 348-57
DOI 10.1002/gcc.20860, PubMed 21305644
A tumor-associated mutation of FYVE-CENT prevents its interaction with Beclin 1 and interferes with cytokinesis
PLoS One, 6 (3), e17086
DOI 10.1371/journal.pone.0017086, PubMed 21455500
Publications 2009
Exon-specific biomarkers in cancer: experimental validation of exon microarray data from colorectal and testicular cancers
A.C. Bakken, Oslo, 83 s.
BIBSYS 094129622